Allspring Global Investments
TVRD

Allspring Global Investments’s Tvardi Therapeutics TVRD Stock Holding History

Allspring Global Investments’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-616
Closed -$62.7K – 2912
2023
Q2 		$62.7K Buy
616
+595
+2,833% +$82K ﹤0.01% 2224
2023
Q1 		$3.69K Buy
+21
New +$7.03K ﹤0.01% 2660
2022
Q3 		– Sell
-76
Closed -$25K – 2966
2022
Q2 		$25K Sell
76
-673
-90% -$236K ﹤0.01% 2436
2022
Q1 		$327K Sell
749
-12
-2% -$4.93K ﹤0.01% 2406
2021
Q4 		$333K Buy
+761
New +$382K ﹤0.01% 2461

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Allspring Global Investments's TVRD Position: Q3 2023 in Review

Allspring Global Investments sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 616 shares — an estimated $62.7K sold.

Allspring Global Investments first reported a position in TVRD in Q4 2021 and held it in 5 quarters. The position peaked at $333K in Q4 2021. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • Allspring Global Investments reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Allspring Global Investments sold 616 Tvardi Therapeutics shares in Q3 2023, an estimated $62.7K.
  • Allspring Global Investments first reported a position in Tvardi Therapeutics in Q4 2021 and held it in 5 quarters.
  • Allspring Global Investments's Tvardi Therapeutics position peaked at $333K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Allspring Global Investments's 13F filing for Q3 2023, filed 27 Oct 2023.